are compound semaglutide going away Despite FDA ruling, compounded GLP-1s still giving Novo and Lilly headaches on the market Switching from compounded semaglutide to

The awkwardness of refusing foods or making special requests diminished as reduced appetite made moderate eating natural rather than forced

The strategy is the latest effort by telehealth companies and their compounding pharmacy partners to extend the runway to profit off of the popular diabetes and obesity drugs

GLP-1s and biological ageing GLP-1s have attracted interest as gerotherapeutics, according to the authors of a small new study that looked at whether semaglutide could slow down biological ageing in people with HIV

Phase 2 data published in 2023 reported mean body-weight reductions of up to 24.2% at 48 weeks on the highest dose tier (Jastreboff et al., NEJM 2023)